Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your electrolytes predict kidney damage after a stroke procedure?

NCT ID NCT07546448

Knowledge-focused Sponsor: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examines whether blood electrolyte levels are linked to kidney damage in people who have a stroke and undergo a clot-removal procedure. Researchers will review medical records from 250 patients treated between 2018 and 2026. The goal is to identify risk factors that could help prevent kidney injury after contrast dye is used.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors identify stroke patients at higher risk for kidney damage after a clot-removal procedure, allowing for closer monitoring or preventive steps.
What could go wrong
This is an observational study, not a treatment trial. It only looks at past data, so it cannot prove cause and effect. Results may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion. The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.

Ages

18 to 100 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Patients diagnosed with acute ischemic stroke * Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026 * Patients with a baseline NIHSS score of 6 or higher * Patients who received iodinated contrast medium during the endovascular procedure * Patients managed under general anesthesia * Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury Exclusion Criteria: * Age younger than 18 years * Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy * APACHE score greater than 25 at the time of the procedure * Known allergy or hypersensitivity to iodinated contrast media * Exposure to iodinated contrast media within the previous 2 weeks * Use of nephrotoxic medications within the previous 2 weeks * History of myocardial infarction or previous stroke * Use of vasopressor/inotropic agents such as dopamine at the time of the procedure * Systemic steroid use at the time of the procedure * Incomplete medical records or missing laboratory data required for evaluation of CI-AKI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke Acute kidney injury Contrast-induced nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fatma Acil

    Diyarbakır, Outside of the US, 21070, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.